Drugs / Anti-BCMA CAR-NK Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05008536 | Oct 2021 → Sep 2022 | plasma cell myeloma | Xinqiao Hospital of Chongqing | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-BCMA CAR-NK Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05008536 ↗ |
| Action | Deplete | “recognize and kill the MM cells by targeting of BCMA” NCT05008536 ↗ |
| Modality | Cell therapy | “BCMA CAR-NK cells（Umbilical \& Cord Blood (CB) Derived CAR-Engineered NK Cells）” NCT05008536 ↗ |